The UK medicines regulator has cleared early access to Gilead Sciences’ coronavirus drug remdesivir for people hospitalised with severe coronavirus infection, although supplies will initially be limited. MHRA has approved the drug under the Early Access to Medicines Scheme (EAMS), used to speed up access to unlicensed drugs for life-threatening or seriously debilitating conditions. The
Gilead Sciences obtained a big achievement with its Hepatitis C treatment Vosevi (drug which comprises of Sofosbuvir/Velpatasvir/Voxilaprevir) becoming the first and only single tablet regimen for patients who have previously failed therapy with direct-acting antivirals (DAA). The drug was approved to treat adults with genotype 1-6 chronic hepatitis virus (HCV) infection as a 12-week regimen
Two drug combinations from Gilead and AbbVie that have the potential to improve treatment of chronic hepatitis C have been given accelerated review in the EU. Gilead’s application is for a three-drug combination of NS5B polymerase inhibitor sofosbuvir, NS5A inhibitor velpatasvir and pan-genotypic protease inhibitor voxilaprevir that could achieve a cure for chronic hepatitis C
Nineteen new therapies, which include an antidote to the blood thinner Pradaxa, a treatment for the rare blood cancer multiple myeloma, and a new drug for Parkinson’s disease. Have taken a leap closer to being granted entry to the EU market. The European Medicines Agency’s Committee for Medicinal Products for Human Use has endorsed approval
